Scynexis names new CEO
This article was originally published in Scrip
Executive Summary
Drug discovery and development company Scynexis has appointed Dr Marco Taglietti CEO, effective from 1 April 2015. Dr Taglietti, a member of Scynexis' board of directors, will succeed Dr Yves Ribeill in the position. Dr Ribeill will remain the company's president and will continue to serve on the company's board. In an unrelated matter Scynexis said Dr Carole Sable, the company's current chief medical officer, is stepping down effective 20 February 2015.
You may also be interested in...
BIO 2016 Notebook: Pricing And Innovation Hot Topics In San Francisco
Scrip spoke with several executives and attended multiple panel discussions in San Francisco during the first full day of BIO's annual international gathering. Drug pricing and enabling innovation emerged as key themes.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.